Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Zeynep Eroglu, MD, discusses the use of a triplet regimen vs standard doublet therapy for the treatment of brain metastases in patients with melanoma.

The FDA recently granted fast track designation to PHST001, an investigational anti-CD24 monoclonal antibody, for the ...

During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with ...

Discover the groundbreaking AMPLITUDE trial results, showcasing niraparib's effectiveness in treating metastatic prostate cancer with minimal safety concerns.

The FDA granted priority review to the combination of lurbinectedin and atezolizumab as a first-line maintenance therapy for ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Samuel M. Rubinstein, MD, discussed the outcomes from the KarMMa-3 trial and real-world patients ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Sophia Kamran, MD, discussed the updated AUA guidelines on salvage therapy for patients with prostate cancer and their ...

A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

TuHURA Biosciences advances its phase 3 trial of IFx-2.0 for Merkel cell carcinoma, aiming to enhance immune response ...